Skip to main content

Master of Public Health

Tamoxifen Initiation After Ductal Carcinoma In Situ.

AUTHORS

Nichols HB , Bowles EJ , Islam J , Madziwa L , Stürmer T , Tran DT , Buist DS , . The oncologist. 2016 2 1; 21(2). 134-40

ABSTRACT

Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly variable and largely unexplained. National guidelines recommend considering tamoxifen for women with estrogen receptor-positive (ER+) DCIS or who undergo excision alone. We evaluated endocrine therapy use after DCIS over a 15-year period in an integrated health care setting to identify factors related to initiation.

Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly variable and largely unexplained. National guidelines recommend considering tamoxifen for women with estrogen receptor-positive (ER+) DCIS or who undergo excision alone. We evaluated endocrine therapy use after DCIS over a 15-year period in an integrated health care setting to identify factors related to initiation.

Tags: